Oncology biotech ArriVent does another China ADC deal, this time with Lepu Biopharma

Kyle LaHucik

Senior Reporter

Bing Yao’s ArriVent BioPharma has inked another licensing deal with a Chinese biopharma. The late-stage oncology biotech is picking up a new antibody-drug conjugate from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Oncology biotech ArriVent does another China ADC deal, this time with Lepu Biopharma

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

GLP-1s can cut the risk of Alzheimer’s. What does that mean for Novo Nordisk?

China's biotech boom is threatening US drugmakers' dominance

US withdrawal from WHO could jeopardize information sharing

J&J’s Spravato hit $1B in revenue in 2024

Inhibrx’s early colorectal cancer data clouded by patient death

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

On­col­o­gy biotech Ar­riVent does an­oth­er Chi­na ADC deal, this time with Lepu Bio­phar­ma

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Oncology biotech ArriVent does another China ADC deal, this time with Lepu Biopharma